torcetrapib/atorvastatin + atorvastatin

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Mixed Hyperlipidemia

Conditions

Mixed Hyperlipidemia

Trial Timeline

Nov 1, 2003 → Dec 1, 2006

NCT ID

NCT00134238

About torcetrapib/atorvastatin + atorvastatin

torcetrapib/atorvastatin + atorvastatin is a phase 3 stage product being developed by Pfizer for Mixed Hyperlipidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00134238. Target conditions include Mixed Hyperlipidemia.

What happened to similar drugs?

2 of 16 similar drugs in Mixed Hyperlipidemia were approved

Approved (2) Terminated (1) Active (13)

✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved

✅TegaserodNovartisApproved

🔄olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3

🔄Lurasidone + PlaceboSumitomo PharmaPhase 3

🔄MK-0524A + Atorvastatin + SimvastatinMerckPhase 3

🔄Inclisiran + Matching Placebo for InclisiranNovartisPhase 3

🔄FluvastatinNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00134485	Phase 3	Completed	Mar 1, 2005	Mar 1, 2006	Hypercholesterolemia, Familial
NCT00134498	Phase 3	Completed	Feb 1, 2005	Nov 1, 2006	Hypertriglyceridemia
NCT00137462	Phase 3	Completed	Nov 1, 2004	Sep 1, 2006	Hyperlipidemia
NCT00134264	Phase 3	Terminated	Jul 1, 2004	Jun 1, 2007	Coronary Disease
NCT00136981	Phase 3	Completed	Dec 1, 2003	Nov 1, 2006	Hypercholesterolemia, Familial
NCT00134238	Phase 3	Terminated	Nov 1, 2003	Dec 1, 2006	Mixed Hyperlipidemia
NCT00134173	Phase 3	Completed	Oct 1, 2003	Sep 1, 2006	Coronary Disease

Competing Products

20 competing products in Mixed Hyperlipidemia

See all competitors

Product	Company	Stage	Hype Score
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	43
olanzapine + lithium + valproate + carbamazepine	Eli Lilly	Phase 3	40
Lurasidone + Placebo	Sumitomo Pharma	Phase 3	40
MK-0524A + Atorvastatin + Simvastatin	Merck	Phase 3	40
Inclisiran + Matching Placebo for Inclisiran	Novartis	Phase 3	40
Tegaserod	Novartis	Approved	43
Fluvastatin	Novartis	Phase 3	40
Atorvastatin + Evolocumab	Amgen	Phase 3	40
Evolocumab + Atorvastatin + Placebo to Evolocumab + Placebo to Atorvastatin	Amgen	Phase 3	40
Blinatumomab in combination with donor lymphocyte infusion	Amgen	Phase 2	27
Evolocumab + Atorvastatin	Amgen	Phase 3	40
Evolocumab + Standard of Care	Amgen	Phase 3	40
Bococizumab + Placebo	Pfizer	Phase 3	32
tafamidis	Pfizer	Pre-clinical	26
IBI306 + placebo + placebo + IBI306	Innovent Biologics	Phase 3	47
KarXT	Bristol Myers Squibb	Phase 3	47
KarXT	Bristol Myers Squibb	Phase 3	47
Gemcitabine + Oxaliplatin	Sanofi	Phase 2	35
XL765 (SAR245409) + Temozolomide	Sanofi	Phase 1	29
SAL003 140 mg + Placebo	Shenzhen Salubris Pharmaceuticals	Phase 3	40